LSD and structural analogs: pharmacological evaluation at D1 dopamine receptors - PubMed (original) (raw)
LSD and structural analogs: pharmacological evaluation at D1 dopamine receptors
V J Watts et al. Psychopharmacology (Berl). 1995 Apr.
Abstract
The hallucinogenic effects of lysergic acid diethylamide (LSD) have been attributed primarily to actions at serotonin receptors. A number of studies conducted in the 1970s indicated that LSD also has activity at dopamine (DA) receptors. These latter studies are difficult to interpret, however, because they were completed before the recognition of two pharmacologically distinct DA receptor subtypes, D1 and D2. The availability of subtype-selective ligands (e.g., the D1 antagonist SCH23390) and clonal cell lines expressing a homogeneous receptor population now permits an assessment of the contributions of DA receptor subtypes to the DA-mediated effects of LSD. The present study investigated the binding and functional properties of LSD and several lysergamide and analogs at dopamine D1 and D2 receptors. Several of these compounds have been reported previously to bind with high affinity to serotonin 5HT2 (i.e., 3H-ketanserin) sites in the rat frontal cortex (K0.5 5-30 nM). All tested compounds also competed for both D1-like (3H-SCH 23390) and D2-like (3H-spiperone plus unlabeled ketanserin) DA receptors in rat striatum, with profiles indicative of agonists (nH < 1.0). The affinity of LSD and analogs for D2 like receptors was similar to their affinity for 5HT2 sites. The affinity for D1 like receptors was slightly lower (2- to 3-fold), although LSD and several analogs bound to D1 receptors with affinity similar to the prototypical D1 partial agonist SKF38393 (K0.5 ca. 25 nM). A second series of experiments tested the binding and functional properties of LSD and selected analogs in C-6 glioma cells expressing the rhesus macaque D1A receptor.(ABSTRACT TRUNCATED AT 250 WORDS)
Similar articles
- Dopamine D1 receptors: efficacy of full (dihydrexidine) vs. partial (SKF38393) agonists in primates vs. rodents.
Watts VJ, Lawler CP, Gilmore JH, Southerland SB, Nichols DE, Mailman RB. Watts VJ, et al. Eur J Pharmacol. 1993 Sep 28;242(2):165-72. doi: 10.1016/0014-2999(93)90076-t. Eur J Pharmacol. 1993. PMID: 7902811 - Hallucinogenic 5-HT2AR agonists LSD and DOI enhance dopamine D2R protomer recognition and signaling of D2-5-HT2A heteroreceptor complexes.
Borroto-Escuela DO, Romero-Fernandez W, Narvaez M, Oflijan J, Agnati LF, Fuxe K. Borroto-Escuela DO, et al. Biochem Biophys Res Commun. 2014 Jan 3;443(1):278-84. doi: 10.1016/j.bbrc.2013.11.104. Epub 2013 Dec 2. Biochem Biophys Res Commun. 2014. PMID: 24309097 - d-Lysergic Acid Diethylamide (LSD) as a Model of Psychosis: Mechanism of Action and Pharmacology.
De Gregorio D, Comai S, Posa L, Gobbi G. De Gregorio D, et al. Int J Mol Sci. 2016 Nov 23;17(11):1953. doi: 10.3390/ijms17111953. Int J Mol Sci. 2016. PMID: 27886063 Free PMC article. Review.
Cited by
- Methods of Lysergic Acid Synthesis-The Key Ergot Alkaloid.
Jastrzębski MK, Kaczor AA, Wróbel TM. Jastrzębski MK, et al. Molecules. 2022 Oct 28;27(21):7322. doi: 10.3390/molecules27217322. Molecules. 2022. PMID: 36364148 Free PMC article. Review. - Acute psilocybin enhances cognitive flexibility in rats.
Torrado Pacheco A, Olson RJ, Garza G, Moghaddam B. Torrado Pacheco A, et al. bioRxiv [Preprint]. 2023 Jan 9:2023.01.09.523291. doi: 10.1101/2023.01.09.523291. bioRxiv. 2023. PMID: 36712091 Free PMC article. Updated. Preprint. - Pharmacological characterization of the LSD analog N-ethyl-N-cyclopropyl lysergamide (ECPLA).
Halberstadt AL, Klein LM, Chatha M, Valenzuela LB, Stratford A, Wallach J, Nichols DE, Brandt SD. Halberstadt AL, et al. Psychopharmacology (Berl). 2019 Feb;236(2):799-808. doi: 10.1007/s00213-018-5055-9. Epub 2018 Oct 8. Psychopharmacology (Berl). 2019. PMID: 30298278 Free PMC article. - Return of the lysergamides. Part IV: Analytical and pharmacological characterization of lysergic acid morpholide (LSM-775).
Brandt SD, Kavanagh PV, Twamley B, Westphal F, Elliott SP, Wallach J, Stratford A, Klein LM, McCorvy JD, Nichols DE, Halberstadt AL. Brandt SD, et al. Drug Test Anal. 2018 Feb;10(2):310-322. doi: 10.1002/dta.2222. Epub 2017 Jul 27. Drug Test Anal. 2018. PMID: 28585392 Free PMC article. - Synergistic, multi-level understanding of psychedelics: three systematic reviews and meta-analyses of their pharmacology, neuroimaging and phenomenology.
Shinozuka K, Jerotic K, Mediano P, Zhao AT, Preller KH, Carhart-Harris R, Kringelbach ML. Shinozuka K, et al. Transl Psychiatry. 2024 Dec 4;14(1):485. doi: 10.1038/s41398-024-03187-1. Transl Psychiatry. 2024. PMID: 39632810 Free PMC article.
References
- Mol Pharmacol. 1992 Apr;41(4):652-9 - PubMed
- Psychopharmacology (Berl). 1978 Oct 31;59(2):113-6 - PubMed
- J Neural Transm Suppl. 1992;36:163-77 - PubMed
- Eur J Pharmacol. 1991 Aug 14;207(4):277-86 - PubMed
- Experientia. 1968 Jul 15;24(7):743-7 - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous